Figure 5
From: Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT
Representative transverse slice images showing lesion-based progression (first row) and partial response (second row) to 2 cycles of [177Lu]Lu-PSMA-617 RLT: (A) baseline [68Ga]Ga-PSMA-11 PET/CT, (B) baseline [18F]FDG PET/CT, and (C) follow-up [18F]FDG PET/CT. First row, red arrows: progressing bone metastases. These lesions had faint [68Ga]Ga-PSMA-11 uptake (SUVmax: 3.47 and 4.00, respectively) and intense [18F]FDG uptake (SUVmax: 11.17 and 8.67, respectively) in the baseline scans (FPQ: 3.22 and 2.17, respectively), and increased [18F]FDG uptake (SUVmax 16.87 and 12.37, respectively; 51% higher and 43% higher, respectively, than at baseline) in the follow-up scan. Second row, green arrows: bone metastasis showing partial response. The lesion, which had intense [68Ga]Ga-PSMA-11 uptake (SUVmax: 22.74) and moderate [18F]FDG uptake (SUVmax: 6.60) in the respective baseline scans (FPQ: 0.29), had decreased [18F]FDG uptake (SUVmax 4.52, 32% lower than at baseline) in the follow-up scan.
